Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies

Nat Med. 2021 Nov;27(11):1872-1873. doi: 10.1038/s41591-021-01565-6.

Authors

Sheng Fu¹, Sheldon E Litwin^{1

2}, Ryan J Tedford³

Affiliations

¹ Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
² Division of Cardiology, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA.
³ Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA. [email protected].

PMID: 34764484
DOI: 10.1038/s41591-021-01565-6

No abstract available

Publication types

Comment

MeSH terms

Heart Failure* / drug therapy
Humans
Hypoglycemic Agents / therapeutic use
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors